Pelthos Therapeutics Inc. Increase (Decrease) in Accounts Payable
Pelthos Therapeutics Inc. (PTHS) reported Increase (Decrease) in Accounts Payable of $2.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$338.00K, a 114.11% decline year-over-year.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $3.16M, a 347.10% increase year-over-year.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$2.67M, a 530.76% decline year-over-year.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $928.00K.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2025 was $1.36M, a 15.01% increase from fiscal 2024.
- Pelthos Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.18M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$338.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $2.82M 10-Q · filed 2026-08-13 | $148.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.16M 10-Q/A · filed 2026-08-13 | $486.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.41M derived: sum of 3 quarters · filed 2026-08-13 | $3.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.75M derived: sum of 2 quarters · filed 2026-03-19 | $649.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.36M 10-K · filed 2026-03-19 |
| 2025-09-30 | $928.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.32M derived: sum of 2 quarters · filed 2026-08-13 | $4.03M 10-Q · filed 2025-11-13 | $4.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.40M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $3.10M 10-Q · filed 2026-08-13 | $3.72M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | $707.00K 10-Q/A · filed 2026-08-13 | $1.33M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2024-12-31 | $621.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.18M 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $558.00K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |